ST. PAUL, Minn., June 25, 2013 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), announced today that its specialty pharmacy, Prime Therapeutics Specialty Pharmacy, has received accreditation from the Accreditation Commission for Health Care (ACHC). Prime's accreditation is effective through May 2016.
"ACHC accreditation reflects our commitment to providing a high level of care for members with complex medical conditions while effectively managing their health care costs," said Duane Barnes, senior vice president, consumer delivery at Prime Therapeutics.
ACHC is a not-for-profit accrediting organization that has stood as a symbol of quality and excellence since 1986. Accreditation is a voluntary activity in which healthcare organizations submit to peer review of internal policies, processes and patient care against national standards.
In addition to its ACHC accreditation, Prime Therapeutics Specialty Pharmacy most recently received accreditation from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry.
Based in Orlando, Fla., Prime Therapeutics Specialty Pharmacy offers a full suite of specialty pharmacy services, from care management to insurance billing to delivery of specialty medicines.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Headquartered in St. Paul, Minn., Prime serves more than 21 million* people. It is collectively owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Prime has been recognized as one of the fastest-growing private companies in the nation.
For more information, visit www.primetherapeutics.com or follow @Prime_PBM on Twitter.
*Effective July 1, 2013.
SOURCE Prime Therapeutics